Literature DB >> 4038625

Flow cytometric studies on modulation of cellular adriamycin retention by phenothiazines.

A Krishan, A Sauerteig, L L Wellham.   

Abstract

Phenothiazines (chlorpromazine and trifluoperazine) enhance the cellular retention and cytotoxicity of adriamycin in P388/S and P388/R cells. Effects on the resistant cells are more pronounced than those on the sensitive cells. Multiparametric flow-cytometric determination of cellular Adriamycin fluorescence shows that the phenothiazine effects are not uniform in a cell population, and cells in later part of the cell cycle traverse (S and G2/M), mitogen-stimulated lymphocytes (as compared to nonstimulated lymphocytes), and ascites (as compared to splenocytes) have greater sensitivity to phenothiazine effects on Adriamycin retention.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4038625

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells.

Authors:  J Shen; C Hughes; C Chao; J Cai; C Bartels; T Gessner; J Subjeck
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

2.  miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells.

Authors:  A A Takwi; Y-M Wang; J Wu; M Michaelis; J Cinatl; T Chen
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

3.  Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma.

Authors:  Michiro Susa; Arun K Iyer; Keinosuke Ryu; Francis J Hornicek; Henry Mankin; Mansoor M Amiji; Zhenfeng Duan
Journal:  BMC Cancer       Date:  2009-11-16       Impact factor: 4.430

4.  Incorporation of chlorpromazine into bilayer liposomes for protection against microsomal metabolism and liver absorption.

Authors:  R A Schwendener
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Apr-Jun       Impact factor: 2.441

5.  Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker.

Authors:  K S Sridhar; A Krishan; T S Samy; R C Duncan; A Sauerteig; G V McPhee; M E Auguste; P W Benedetto
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Doxorubicin-conjugated bacteriophages carrying anti-MHC class I chain-related A for targeted cancer therapy in vitro.

Authors:  Achara Phumyen; Siriporn Jantasorn; Amonrat Jumnainsong; Chanvit Leelayuwat
Journal:  Onco Targets Ther       Date:  2014-11-28       Impact factor: 4.147

7.  Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.

Authors:  R Ganapathi; H Schmidt; D Grabowski; M Melia; N Ratliff
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.